CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral’s internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals.
“Isabel brings a wealth of experience leading internal and external cross-functional development teams, having led translational research programs within drug discovery and development companies for more than 20 years,” said Arthur H. Tinkelenberg, Ph.D., President, Chief Executive Officer and Co-Founder of Enumeral. “In addition, throughout her career, she has formed and managed diverse, multi-year research alliances with several pharmaceutical companies, experience which will be instrumental to our business and external R&D goals.”
“I am happy to join the Enumeral team and contribute to the advancement of our programs and look forward to developing strategic collaborations with partners who share our vision for using ex vivo human profiling to guide development of best-in-class immunotherapies in a number of disease areas," said Dr. Chiu. "We expect our pipeline programs will involve intensive coordination of translational research, drug discovery, bioinformatics and clinical insights from patient-derived profiling data.”
Prior to joining Enumeral, Dr. Chiu, served 10 years at AVEO Pharmaceuticals, most recently as Vice President, Translational Research, where she was instrumental in the creation of the company's proprietary “Human Response Platform” and was responsible for applying preclinical insights to guide the company’s discovery, development and biomarker programs. Prior to joining AVEO, Dr. Chiu spent 10 years with GPC-Biotech, formerly Mitotix Inc., where she served as Director of Target Discovery. At GPC-Biotech, Dr. Chiu established functional phenotypic screens for cancer drug discovery and played key roles in numerous multi-year alliances with external collaborators. Dr. Chiu has broad experience in shaping and leading R&D alliances with external partners, including multi-year collaborations with Merck Research Laboratories, OSI, Astellas and Altana Pharma. She completed her post-doctoral training at the Johns Hopkins School of Medicine and Howard Hughes Medical Institute, and is the author of numerous publications and issued patents. Dr. Chiu received her B.A. in biochemistry from Brandeis University and her Ph.D. in biology from the Massachusetts Institute of Technology.
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. Our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements, which can be identified with words and phrases such as "will," "expect," "potentially," "look forward" and "believe" reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.